首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN

【24h】

COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN

机译：HER2 +乳腺癌患者对Pertuzubab，曲妥珠单抗和多西他赛进行新辅助化疗的费用效用分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2016年第7期|共1页
作者
Colomer R.; Ciruelos E.; De la Haba J.; Martin M.; De Salas-Cansado M.; Munoz-Molina B.; Albanell J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN [J] . Colomer R., Ciruelos E., De la Haba J., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：HER2 +乳腺癌患者对Pertuzubab，曲妥珠单抗和多西他赛进行新辅助化疗的费用效用分析
2. Recurrence rates in patients with HER2+breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study [J] . OShaughnessy Joyce, Robert Nicholas, Annavarapu Srinivas, Breast cancer research and treatment. . 2021,第3期

机译：患有HER2 +乳腺癌患者的复发率，在Neoadjuvant Pertuzumab Plus Trastuzumab之后实现了病理完全反应，其次是佐剂曲妥珠单抗：真实世界的证据研究
3. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial [J] . Hurvitz Sara A., Martin Miguel, Symmans W. Fraser, The lancet oncology . 2018,第1期

机译：Neoadjuvant Trastuzumab，Pertuzumab和化疗与Her2阳性乳腺癌（Kristine）的患者患有Trastuzumab Emtansine Plus Pertuzumab：随机，开放标签，多期，第3阶段试验
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Biomarker analysis of the NeoSphere study: pertuzumab trastuzumab and docetaxel versus trastuzumab plus docetaxel pertuzumab plus trastuzumab or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer [O] . Giampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, 2017

机译：NeoSphere研究的生物标志物分析：帕妥珠单抗曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛用于HER2阳性乳腺癌的新辅助治疗
7. Cost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spaincost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spain [O] . R Colomer, E Ciruelos, J De la Haba, 2016

机译：西班牙治疗腹膜康氏症患者腹膜癌患者腹膜癌，胸瘤和多西紫杉醇患者腹膜癌患者的新辅助化疗的成本实用性分析

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号